Clinical Trial Search

Primary: Major Symptom Score (MSS) Assessed by the Investigator — 2.38; 3.41 units on a scale

Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set — -4.8213; -4.7394; -4.7758; -5.0180 Score on a scale

Primary: Change in Rhinosinusitis Disability Index (RSDI) Score — -8.000; -14.82 units on a scale — p=0.505

Primary: Number of Participants With a Clinical Outcome of "Cure" at Test of Cure (TOC: Day 15) — 23; 3; 0 Participants

Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants

Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2) — -2.97; -3.36; -3.33 units on a scale — p=0.008

Primary: SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3 — 1.12; 1.14 Units on a scale — p=0.83

Primary: Sinonasal Outcome Test (SNOT 20) — 50.33; 53.14; 37 Score out of total 100

Primary: Number of Patients Recommended for Sinus Surgery After 3 Weeks of Antibiotic Therapy — 7; 8; 0; 6 Participants

Primary: Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose — -2.70; -2.61 Scores on a scale — p=0.7782

Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale

Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — 0; -0.8 score on a scale

Primary: Quality of Life (QoL) Outcomes Between Adenoidectomy + Maxillary Sinus Irrigation With or Without the Use of Balloon Dilation or Maxillary Sinus Ostia. — 2.48; 2.5…

Primary: Change in Nasal Polyp Score — .9; .3 score on a scale

Primary: Proportion of Children With Clinical Relapse on Day 10 (Short Course) vs Day 20 (Long Course) — 13; 8; 9; 10 Participants

Primary: Change in Sino-nasal Outcome Test-22 Score Between Baseline and 6 Weeks, Then 6 Weeks to 12 Weeks. — 59.3; 52.9; 45.4; 51.8 units on a scale

Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps. — -2.13; -2.06 score on a scale

Primary: Subjects Who Developed Antibiotic Resistance Organisms — 0; 0; 1; 0 Participants

Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…

Primary: Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score — -18.1; -18.3 score on a scale — p=0.9499

Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — -2; -0.8 units on a scale

Primary: Mean Reduction in SNOT-20 Scores — 1.8; 5.5 units on a scale — p=0.23

Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps — -2.73; -1.61 Change from Baseline in…

Primary: Subjective Improvement - Day 3 (Rating of "a Lot Better" or "no Symptoms") — 33; 31; 22; 33 Participants

Primary: The Change From Baseline in the Mean of the 3 Single Symptom Scores (Blocked Nose, Sneezing and Running Nose) at the Closing/Final Visit. — -2 units on a scale

Primary: Sino-nasal Outcome Test (SNOT-22) Over Time — 43.8; 42.9; 39.7; 38.5 score on a scale — p=0.819

Primary: Comparison of Change in Chronic Sinusitis Survey (CSS) Score at 24 Weeks Compared to Baseline — 41.9; 27.0 Scores on a scale

Primary: Total Subjective Symptoms Visual Analog Scores (VAS) — 20.4; 20.7; 9.7; 8.9 score on a scale

Primary: TOTAL POLYP SCORE (TPS) — 4.67; 5.24 units on a scale — p=<0.05

Primary: Number of Participants in Compliance With Medical Recommendations — 20; 10 participants